Reaction

Skin Papilloma reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 3,964 reports · 107 co-occurring drugs

As of the last recalculation, Skin Papilloma appears in 3,964 FAERS reports alongside 107 co-occurring drug terms. The strongest observed disproportionality signal is VEMURAFENIB (PRR 108.6).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Vemurafenib	234	108.6	110.7
Dimenhydrinate	36	17.9	17.9
Dabrafenib	42	10.6	10.6
Encorafenib	19	10.1	10.1
Cyclobenzaprine Hydrochloride	17	10.0	10.0
Ibuprofen Tablets, Coated	79	9.9	10.0
Ibuprofen Sodium	79	9.9	9.9
Ketoconazole Foam	27	9.7	9.7
Ketoconazole Cream, 2%	27	9.6	9.6
Alemtuzumab	34	9.3	9.3
Ketoconazole	30	9.2	9.2
Leflunomide	166	8.6	8.7
Tocilizumab	169	8.1	8.1
Chlorhexidine Gluconate	14	8.1	8.1
Tretinoin	12	7.8	7.8
Mercaptopurine	25	7.6	7.6
Daspone	13	7.0	7.0
Dapsone Gel, 5%	13	7.0	7.0
Dapsone	14	6.9	6.9
Tacrolimus Extended-Release Capsules	158	6.9	6.9
Tacrolimus Ointment 0.1%	157	6.9	6.9
Naproxen	98	6.7	6.7
Fingolimod Hcl	106	6.6	6.6
Azathioprine	105	6.4	6.4
Tacrolimus	181	6.3	6.3
Fexofenadine Hcl	11	6.3	6.3
Mycophenolate Mofetil	155	6.2	6.2
Mycophenolate Mofetil Hydrochloride	155	6.2	6.2
Hydroxychloroquine	85	6.1	6.1
Zinc Gluconate	30	6.1	6.1
Sorafenib	23	5.8	5.8
Diphenoxylate Hydrochloride And Atropine Sulfate	15	5.8	5.8
Isotretinoin	53	5.7	5.7
Zinc	26	5.6	5.6
Zinc Chloride	26	5.5	5.5
Cimetidine	10	5.5	5.5
Trametinib	25	5.5	5.5
Hydroxychloroquine Sulfate	92	5.4	5.4
Canakinumab	11	5.4	5.4
Abatacept	137	5.3	5.3
Mycophenilic Acid	21	5.3	5.3
Clindamycin Phosphate	33	5.2	5.2
Teduglutide	13	5.1	5.1
Itraconazole	11	5.0	5.0
Desloratadine	10	4.9	4.9
Clindamycin	25	4.6	4.7
Finasteride	52	4.6	4.6
Atovaquone	7	4.6	4.6
Anti-Thymocyte Globulin (Rabbit)	7	4.6	4.6
Nilotinib	25	4.5	4.5
Cyclosporine	91	4.4	4.4
Ursosiol	16	4.3	4.3
Infliximab-Dyyb	24	4.3	4.3
Valganciclovir Hydrochloride Powder,	10	4.3	4.3
Mycophenolic Acid	26	4.3	4.3
Adalimumab	515	4.2	4.2
Liothyronine Sodium	7	4.2	4.2
Adalimumab-Fkjp	37	4.2	4.2
Folic Acid	191	4.2	4.2
Tofacitinib	142	4.2	4.2
Adalimumab-Aaty	37	4.1	4.1
Ursodiol	17	4.1	4.1
Moxifloxacin	11	4.1	4.1
Naproxen Sodium	109	4.1	4.1
Methotrexate	308	4.1	4.1
Losartan Potassium And Hydrochlorothiazide	9	4.1	4.1
Epoetin Alfa	9	4.0	4.0
Risankizumab-Rzaa	61	4.0	4.0
Methotrexate Sodium	343	4.0	4.0
Infliximab	157	3.9	3.9
Biotin	23	3.9	3.9
Acetaminophen And Codeine	9	3.9	3.9
Adalimumab-Adaz	38	3.8	3.8
Secukinumab	111	3.7	3.7
Valganciclovir	13	3.6	3.6
Valganciclovir Hydrochloride	13	3.6	3.6
Tofacitinib Citrate	9	3.6	3.6
Testosterone	16	3.6	3.6
Mesalamine	38	3.6	3.6
Isoniazid	11	3.6	3.6
Upadacitinib	54	3.5	3.5
Amikacin	11	3.4	3.4
Triamcinolone Acetonide Ointment Usp, 0.05%	15	3.4	3.4
Sunitinib Malate	25	3.4	3.4
Posaconazole Delayed-Release	7	3.4	3.4
Dorzolamide Hydrochloride And Timolol Maleate	5	3.3	3.3
Raltegravir	10	3.2	3.2
Regorafenib	7	3.2	3.2
Certolizumab Pegol	69	3.1	3.1
Ustekinumab	60	3.1	3.1
Ruxolitinib	42	3.1	3.1
Etonogestrel And Ethinyl Estradiol	13	3.1	3.1
Etanercept	323	3.0	3.0
Ocrelizumab	35	3.0	3.0
Triamcinolone Acetonide	16	2.7	2.7
Apalutamide	6	2.7	2.7
Fexofenadine Hydrochloride	11	2.7	2.7
Atomoxetine Hydrochloride	11	2.4	2.4
Cabozantinib	22	2.4	2.4
Dupilumab	187	2.1	2.1
Ozanimod Hydrochloride	3	1.9	1.9
Bimekizumab	6	1.5	1.5
Apremilast	38	1.4	1.4
Velpatasvir And Sofosbuvir	3	1.2	1.2
Salicylic Acid	11	1.1	1.1
Minoxidil Foam 5% (Womens)	6	1.0	1.0
Adapalene	9	0.3	0.3

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.